Breast cancer

Global Tissue Diagnostics Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Monday, September 21, 2020 - 3:06pm

Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040

Key Points: 
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    Global Number of New Cancer Cases (in Million) in Men by Cancer Site: 2018
    Global Number of New Cancer Deaths (in Million) in Men by Cancer Site: 2018
    Global Number of New Cancer Cases (in Million) in Women by Cancer Site: 2018
    Global Number of New Cancer Deaths (in Million) in Women by Cancer Site: 2018
    Aging Population and Changing Lifestyles Drive Cancer Incidence, Fueling Prospects for Tissue Diagnostics Market
    Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    Growing Significance of Personalized Medicine: An Opportunity for Tissue Diagnostics Market

RevitaLash® Cosmetics Announces New Additions to Annual Program Benefiting Breast Cancer Awareness

Monday, September 21, 2020 - 2:00pm

VENTURA, Calif., Sept. 21, 2020 /PRNewswire/ -- In addition to their ongoing year-round support and commitment to breast cancer awareness, RevitaLash Cosmetics announces its annual Pink Program for 2020 beginning August 1st running through October 31st.

Key Points: 
  • VENTURA, Calif., Sept. 21, 2020 /PRNewswire/ -- In addition to their ongoing year-round support and commitment to breast cancer awareness, RevitaLash Cosmetics announces its annual Pink Program for 2020 beginning August 1st running through October 31st.
  • RevitaLash Cosmetics has made it its mission to donate a portion of the proceeds from product sales to Breast Cancer Awareness year-round.
  • "The RevitaLash Cosmetics family sees Breast Cancer Awareness as an evergreen cause with the common goal of directly improving lives of those dealing with a difcult diagnosis, and eradicating breast cancer."
  • A supporter of non-profit breast cancer initiatives, RevitaLash Cosmetics donates a portion of proceeds to research and education initiatives, giving back to the breast cancer community year-round, not just in October.

RevitaLash® Cosmetics Announces New Additions to Annual Program Benefiting Breast Cancer Awareness

Monday, September 21, 2020 - 2:00pm

VENTURA, California, Sept. 21, 2020 /PRNewswire/ -- In addition to their ongoing year-round support and commitment to breast cancer awareness, RevitaLash Cosmetics announces its annual Pink Program for 2020 beginning August 1st running through October 31st.

Key Points: 
  • VENTURA, California, Sept. 21, 2020 /PRNewswire/ -- In addition to their ongoing year-round support and commitment to breast cancer awareness, RevitaLash Cosmetics announces its annual Pink Program for 2020 beginning August 1st running through October 31st.
  • RevitaLash Cosmetics has made it its mission to donate a portion of the proceeds from product sales to Breast Cancer Awareness year-round.
  • "The RevitaLash Cosmetics family sees Breast Cancer Awareness as an evergreen cause with the common goal of directly improving lives of those dealing with a difcult diagnosis, and eradicating breast cancer."
  • A supporter of non-profit breast cancer initiatives, RevitaLash Cosmetics donates a portion of proceeds to research and education initiatives, giving back to the breast cancer community year-round, not just in October.

Establishment Labs Announces Independent Publication Detailing New Advancements in Hybrid Breast Reconstruction Technique Using Motiva Ergonomix Implants

Monday, September 21, 2020 - 1:00pm

Utilizing the two-step, prepectoral reconstruction approach, the study found that Motiva Ergonomix implants allowed better control of the final breast shape, and complications related to submuscular approaches were avoided.

Key Points: 
  • Utilizing the two-step, prepectoral reconstruction approach, the study found that Motiva Ergonomix implants allowed better control of the final breast shape, and complications related to submuscular approaches were avoided.
  • The viscoelastic properties of the Motiva Ergonomix breast implant allow it to adapt better to gravitational force and mimic natural movement.
  • We are thrilled to see the aesthetic results of this independent study using our Motiva Ergonomix implants in hybrid breast reconstruction.
  • Hybrid breast reconstruction, sometimes referred to as composite breast reconstruction, provides a solution for rebuilding the breast with natural living fat combined with a supplemental breast implant to give added size and projection to the new breast.

Susan G. Komen® Unveils “Live Pink” Program for 2020, Providing Easy Way to Support Fight Against Breast Cancer

Monday, September 21, 2020 - 1:00pm

Susan G. Komen , the worlds leading breast cancer organization, unveiled its 2nd Annual, Live Pink program, in time for Octobers National Breast Cancer Awareness Month.

Key Points: 
  • Susan G. Komen , the worlds leading breast cancer organization, unveiled its 2nd Annual, Live Pink program, in time for Octobers National Breast Cancer Awareness Month.
  • As more people are staying home and shopping online this year, the program provides consumers who still want to support the fight against breast cancer an easy way to purchase products that support Komen in its mission to find the cures to breast cancers.
  • Komens Live Pink program showcases products and services that directly benefit the fight against breast cancer by funding breakthrough research and providing critical support for people facing breast cancer today.
  • Susan G. Komen is the worlds leading nonprofit breast cancer organization, working to save lives and end breast cancer forever.

CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

Monday, September 21, 2020 - 2:14am

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses.

Key Points: 
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses.
  • The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans.
  • In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

Saturday, September 19, 2020 - 3:30pm

Trodelvy also demonstrated a statistically significant improvement in ORR (35%) and CBR (45%) compared to chemotherapy (5% and 9%, respectively).

Key Points: 
  • Trodelvy also demonstrated a statistically significant improvement in ORR (35%) and CBR (45%) compared to chemotherapy (5% and 9%, respectively).
  • Adverse events leading to treatment discontinuation were low and similar (Trodelvy 4.7% vs TPC 5.4%) in both arms of the study.
  • The international, open-label confirmatory Phase 3 study enrolled more than 500 patients with metastatic triple-negative breast cancer who had received at least two prior therapies for metastatic disease.
  • Immunomedics has an extensive development program for Trodelvy, including multiple ongoing studies in triple-negative breast cancer, metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

Thursday, September 17, 2020 - 11:05pm

Our hope is to advance our broad tislelizumab development program in lung cancer to potentially improve treatment outcomes for the most prevalent cancer, both globally and in China.

Key Points: 
  • Our hope is to advance our broad tislelizumab development program in lung cancer to potentially improve treatment outcomes for the most prevalent cancer, both globally and in China.
  • Pamiparib demonstrated strong antitumor activity in patients with advanced ovarian cancer, having achieved clinically meaningful and durable responses in both platinum-sensitive and platinum-resistant patients with BRCA1/2 mutation.
  • The preliminary results presented at ESMO 2020 were from a Phase 2 dose-expansion portion of a Phase 1/2 trial of pamiparib in patients with advanced ovarian cancer, fallopian cancer, and primary peritoneal cancer or advanced triple negative breast cancer (NCT03333915).
  • To learn more about the data presented at the ESMO Virtual Congress 2020 and BeiGenes clinical pipeline, visit our virtual booth at https://beigenemedical.eu/ .

Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer

Thursday, September 17, 2020 - 9:00pm

POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.

Key Points: 
  • POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.
  • B-PRECISE-01 is an open-label, multicenter, phase Ib, dose escalation and expansion study conducted in patients withHER2-positive, PIK3CAmutated, advanced or metastatic breast cancer, which has progressed after at least two lines of anti-HER2-based therapy.
  • The primary objectives of the study were to determine the safety and the recommended Phase 2 dose (RP2D) of MEN1611 in combination with trastuzumab +/- fulvestrant.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

SEAS Cooling Face Covers Partners With The American Breast Cancer Foundation To Raise Breast Cancer Awareness Through Face Coverings In Los Angeles, California

Thursday, September 17, 2020 - 5:30pm

LOS ANGELES, Sept. 17, 2020 /PRNewswire/ --SEAS Cooling Face Covers, the California-based clothing line specializing in innovative face coverings proudly announces it has established a partnership with The American Breast Cancer Foundation a 501(c)3non-profit organization headquartered in Columbia, MD.

Key Points: 
  • LOS ANGELES, Sept. 17, 2020 /PRNewswire/ --SEAS Cooling Face Covers, the California-based clothing line specializing in innovative face coverings proudly announces it has established a partnership with The American Breast Cancer Foundation a 501(c)3non-profit organization headquartered in Columbia, MD.
  • With this exciting partnership, SEAS Cooling Face Covers will carry out The American Breast Cancer Foundation's important mission of raising breast cancer awareness through the sales of their pink face coverings sold exclusively through their website.
  • Each year, both men and women nationwide receive lifesaving services provided by The American Breast Cancer Foundation to aid in the early detection and survival of breast cancer.
  • ABCF is excited that SEAS Cooling Face Cover's generosity will help those who have nowhere else to turn.